Basal Cell Carcinoma Chemoprevention Trial Funded - VA Providence Healthcare System
Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

VA Providence Healthcare System

 

Basal Cell Carcinoma Chemoprevention Trial Funded

January 15, 2021

Print Version (PDF)

FOR IMMEDIATE RELEASE
Jan. 15, 2021

VA Providence Healthcare System
830 Chalkstone Ave
Providence, RI 02908

Contact:
Winfield S. Danielson III
401-457-3369
winfield.danielsoniii@va.gov

Basal Cell Carcinoma Chemoprevention Trial Funded

PROVIDENCE, R.I. -- Researchers from VA healthcare systems across the country will participate in a basal cell carcinoma preventive medication trial that received a funding decision Jan. 8.

Study chair Dr. Martin A. Weinstock, chief of Dermatology Research for the VA Providence Healthcare System, and professor of Dermatology and Epidemiology at Brown University, and co-chair Dr. Robert Dellavalle, chief of Dermatology for the VA Eastern Colorado Health Care System, and professor of Dermatology and Public Health at the University of Colorado School of Medicine, will research imiquimod, a topical medication with minimal side effects, as a preventive measure against basal cell carcinoma, known as BCC, which is the most common cancer in the United States.

The six-year, $34 million trial, funded by the VA Cooperative Studies Program, will recruit more than 1,600 participants at 17 VA medical centers, including male and female veterans at high risk for BCC. The study will follow participants actively for three years, with an additional year of passive follow-up.

"This study is important for VA because active duty military and Veterans are at higher risk for developing basal cell carcinoma," said Weinstock. "If this trial finds that imiquimod is successful at preventing BCC, it would fundamentally transform our approach to the disease."

BCC generally occurs on the face and requires surgery to avoid serious complications. If the medication proves effective, it may avoid these complications, reduce skin damage and scarring, and reduce the need for medical visits and the resulting costs, as well. In addition to evaluating effectiveness of the treatment, researchers will collect genetic material from some of the participants to determine factors that may indicate greater risk reduction and better tolerance of imiquimod therapy, to help target therapy to those with greater potential for BCC prevention from the medication with fewer bothersome side effects.


Photo caption (photos availalbe upon request)...
Dr. Martin A. Weinstock, chief of Dermatology Research for the VA Providence Healthcare System, and professor of Dermatology and Epidemiology at Brown University, received an award Jan. 8 for a six-year, $34 million trial he chairs with co-chair Dr. Robert Dellavalle, chief of Dermatology for the VA Eastern Colorado Health Care System, and professor of Dermatology and Public Health at the University of Colorado School of Medicine, to investigate the effectiveness of imiquimod as a preventive measure against basal cell carcinoma at VA health care systems across the country. (Photos courtesy of Dr. Martin Weinstock and Dr. Robert Dellavalle)

About the VA Cooperative Studies Program: The CSP is the Division of VA Research and Development responsible for planning and conducting large multicenter clinical trials and epidemiological studies in the Department of Veterans Affairs. Its mission is to advance the health and care of Veterans through cooperative research studies that produce innovative and effective solutions to Veteran and national healthcare problems. More information is available at https://www.research.va.gov/programs/csp/default.cfm

###